I-MAB (NAS:IMAB)
$ 1.055 -0.04 (-3.64%) Market Cap: 81.84 Mil Enterprise Value: -118.19 Mil PE Ratio: 0 PB Ratio: 0.35 GF Score: 35/100

I-Mab SITC Data Conference Call Transcript

Nov 09, 2020 / 01:30PM GMT
Release Date Price: $32.94 (-7.71%)
Operator

Hello, and welcome to the I-Mab Company Update Conference Call. (Operator Instructions) Please note, today's event is being recorded.

I would now like to turn the conference over to your host today, Leah Liu. Please go ahead, ma'am.

Leah Liu
- Senior IR Director

Hi, everyone. This is Leah. I'm the IR Director for I-Mab. Welcome to the call, and thank you for joining us.

On the call today, we have our Founder and Chairman, Dr. Jingwu Zang; our CEO, Dr. Joan Shen; our CFO, Mr. Jielun Zhu; and our U.S. Site Head and the Project Lead for our lemzoparlimab project in the U.S., Claire Xu.

So I guess without further ado, I'll hand over the mic to Dr. Zang to give you a description on our recently released -- well, just released data at SITC on our U.S. project for lemzoparlimab. So Dr. Zang?

Jingwu Zhang Zang
I-Mab - Founder, Honorary Chairman & Director

Thank you, Leah. First of all, I'd like to thank you all for joining us today for this call. We are very pleased to present and to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot